Publication:
Sex, immunity, and cancer

dc.contributor.authorPinto, JA
dc.contributor.authorAraujo, JM
dc.contributor.authorGómez, HL
dc.date.accessioned2025-01-02T14:42:11Z
dc.date.available2025-01-02T14:42:11Z
dc.date.issued2022
dc.description.abstractThe composition of the tumor microenvironment is the complex result of the interaction between tumoral and host factors. Since there are several differences in the regulation of gene circuits between sexes, mainly influenced by sex hormones, the tumor-host interaction presents some differences, leading tumors to evolve under different conditions. Nowadays, it is well known the existence of sexual dimorphism in the regulation of the immune system, where women present an improved immunity to various infectious agents and, on the other hand, a higher incidence of autoimmune diseases than men. In oncology, differences in cancer susceptibility, response to treatment, and clinical outcomes between men and women patients are well known. Recently, sex-specific differences have also been reported in mutations in driver genes and the prognostic value of several biomarkers. Sex has been a widely forgotten biomarker in cancer therapy, but it has recently acquired great relevance due to the different results seen in immunotherapy treatment. © 2021 Elsevier B.V.
dc.formatapplication/pdf
dc.identifier.doi10.1016/j.bbcan.2021.188647
dc.identifier.journalBiochimica et Biophysica Acta - Reviews on Cancer
dc.identifier.urihttps://hdl.handle.net/20.500.14703/284
dc.language.isoeng
dc.publisherElsevier B.V.
dc.publisher.countryUK
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBiomarkers
dc.subjectGenomics
dc.subjectSexual dimorphism
dc.subjectTumor mutational burden
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.02.21
dc.titleSex, immunity, and cancer
dc.typeinfo:eu-repo/semantics/review
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication

Files